

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
14503-019US1Application No.
10/530,849**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37,600 \$1.98(b))

Applicant
Michele Orlando et al.Filing Date
January 19, 2006Group Art Unit
1623**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1.	5,880,270	03/09/99	Berninger et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	2.	WO 03/31464	04/17/03	WO				
	3.	WO 03/31581	04/17/03	WO				
	4.	WO 04/24776	03/25/04	WO				
	5.	WO 04/24777	03/25/04	WO				
	6.	WO 04/30701	04/15/04	WO			Abst.	
	7.	WO 04/33651	04/22/04	WO				
	8.	WO 05/14024	02/17/05	WO				
	9.	WO 05/14035	02/17/05	WO				
	10.	WO 05/14050	02/17/05	WO				
	11.	WO 05/14655	02/17/05	WO				
	12.	WO 05/74993	08/18/05	WO			Abst.	
	13.	WO 05/92390	10/06/05	WO				
	14.	WO 06/108052	10/12/06	WO				
	15.	0 127 839	07/15/92	EP				
	16.	0 218 825	04/22/87	EP				
	17.	0 342 557	11/23/94	EP				
	18.	0 549 721	04/13/94	EP				
	19.	1 424 086	06/02/04	EP				
	20.	2 233 725	09/30/99	CA				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	21.	Adamczyk and Fishpugh, "A Solid Supported Synthesis of Thiol Esters," <u>Tetrahedron Lett.</u> , 1996, 37(25):4305-4308

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-019US1	Application No. 10/530,849
	Applicant Michele Orlando et al.		
	Filing Date January 19, 2006	Group Art Unit 1623	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	22.	Aly et al., "Hemophilia A due to mutations that create new N-glycosylation sites," <u>Proc. Natl. Acad. Sci. USA</u> , 1992, 89:4933-4937
	23.	Andersson et al., "Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma," <u>Proc. Natl. Acad. Sci. USA</u> , 1986, 83:2979-2983
	24.	Armitage, "Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 1998, 92(12):4491-4508
	25.	Balland et al., "Characterisation of two differently processed forms of human recombinant factor IX synthesised in CHO cells transformed with a polycistronic vector," <u>Eur. J. Biochem.</u> , 1988, 172(3):565-572
	26.	Bauer and Rosenberg, "Role of Antithrombin III as a Regulator of In Vivo Coagulation," <u>Semin. Hematol.</u> , 1991, 28:10-18
	27.	Berg et al., "Engineering the proteolytic specificity of activated protein C improves its pharmacological properties," <u>Proc. Natl. Acad. Sci. USA</u> , 2003, 100(8):4423-4428
	28.	Bhattacharyya et al., "Recombinant Factor VIII for Haemophilia <i>An Overview of Production Technologies</i> ," <u>CRIPS</u> , 2003, 4(3):2-8
	29.	Björk and Danielsson, "Antithrombin and related inhibitors of coagulation proteinases," <u>Proteinase Inhibitors</u> , 1986, Chapter 17, pps. 489-513
	30.	Boorsma et al., "Bioprocess Applications of a Sindbis Virus-Based Temperature-Inducible Expression System," <u>Biotech. Bioeng.</u> , 2002, 79(6): 602-609
	31.	Carrell et al., "Human α_1 -antitrypsin: carbohydrate attachment and sequence homology," <u>FEBS Lett.</u> , 1981, 135(2):301-303
	32.	Carrell et al., "Structural Mobility of Antithrombin and its Modulation by Heparin," <u>Thromb. Haemost.</u> , 1997, 78:516-519
	33.	Carver et al., "Expression of human α_1 antitrypsin in transgenic sheep," <u>Cytotechnology</u> , 1992, 9:77-84
	34.	Castillo et al., "Sensitive Substrates for Human Leukocyte and Porcine Pancreatic Elastase: A Study of the Merits of Various Chromophoric and Fluorogenic Leaving Groups in Assays for Serine Proteases," <u>Anal. Biochem.</u> , 1979, 99:53-64
	35.	Cebon et al., "Granulocyte-Macrophage Colony Stimulating Factor from Human Lymphocytes. The effect of glycosylation on receptor binding and biological activity," <u>J. Biol. Chem.</u> , 1990, 265(8):4483-4491
	36.	Chamow and Ashkenazi, <u>Antibody Fusion Proteins</u> , 1999, Wiley & Sons, Inc. (TOC Only)
	37.	Chan et al., "Preparation of <i>O</i> -esters from the corresponding thiol esters: <i>tert</i> -butyl cyclohexanecarboxylate," <u>Organic Syntheses, Coll.</u> , 1990, 7:87-93
	38.	Chen et al., "Purification of α_1 Proteinase Inhibitor from Human Plasma Fraction IV-1 by Ion Exchange Chromatography," <u>Vox Sang.</u> , 1998, 74:232-241
	39.	Choay et al., "Structural studies on a biologically active hexasaccharide obtained from heparin," <u>Ann. NY Acad. Sci.</u> , 1981, 370:644-649
	40.	Choay et al., "Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity," <u>Biochem. Biophys. Res. Commun.</u> , 1983, 116(2):492-499

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-019US1	Application No. 10/530,849
		Applicant Michele Orlando et al.	
		Filing Date January 19, 2006	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	41.	Colman, "Production of therapeutic proteins in the milk of transgenic livestock," <u>Biochem. Soc. Symp.</u> , 1998, 63:141-147
	42.	Conradt et al., "Expression of Human Interleukin-2 in Recombinant Baby Hamster Kidney, Ltk ⁺ , and Chinese Hamster Ovary Cells. Structure of O-linked carbohydrate chains and their location within the polypeptide," <u>J. Biol. Chem.</u> , 1989, 264(29):17368-17373
	43.	Corey and Clark, "A new method for the synthesis of 2-pyridinethiol carboxylic esters," <u>Tetrahedron Lett.</u> , 1979, 31:2875-2878
	44.	de Koning et al., "An approach to the synthesis of peptide-PNA-peptide conjugates via native ligation," <u>Tetrahedron Lett.</u> , 2002, 43(45): 8173-8176
	45.	Denzlinger et al., "Differential Activation of the Endogenous Leukotriene Biosynthesis by Two Different Preparations of Granulocyte-Macrophage Colony-Stimulating Factor in Healthy Volunteers," <u>Blood</u> , 1993, 81(8):2007-2013
	46.	Donahue et al., "Effects of N-linked Carbohydrates on the In Vivo Properties of Human GM-CSF," <u>Cold Spring Harbor Symp. Quant. Biol.</u> , 1986, 51:685-692
	47.	Edmunds et al., "Transgenically Produced Human Antithrombin: Structural and Functional Comparison to Human Plasma-Derived Antithrombin," <u>Blood</u> , 1998, 91(12):4561-4571
	48.	Ernst et al. (eds.), <u>Carbohydrates in Chemistry and Biology</u> , 2000, Part I, Vol. 1-2, Wiley-VCH Weinheim (TOC only)
	49.	European Pharmacopoeia, 2001, 911-917
	50.	Forno et al., "N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line," <u>Eur. J. Biochem.</u> , 2004, 271(5):907-919
	51.	Franzen and Svensson, "Structural Studies on the Carbohydrate Portion of Human Antithrombin III," <u>J. Biol. Chem.</u> , 1980, 255(11):5090-5093
	52.	Fujiki et al., "Studies on the disulfide bonds in human pituitary follicle-stimulating hormone," <u>Biochim. Biophys. Acta</u> , 1980, 624: 428-435
	53.	Goldstein and Gelb, "An alternate preparation of thioester resin linkers for solid-phase synthesis of peptide C-terminal thioacids," <u>Tetrahedron Lett.</u> , 2000, 41(16):2797-2800
	54.	Goronzy et al., "T-Cell Derived Lymphokines as Regulators of Chronic Inflammation: Potential Targets for Immunomodulation?" <u>Am. J. Ther.</u> , 1996, 3(2):109-114
	55.	Gribben et al., "Development of antibodies to unprotected glycosylation sites on recombinant GM-CSF," <u>Lancet</u> , 1990, 335:434-437
	56.	Harris et al., "Pegylation. A novel process for modifying pharmacokinetics," <u>Clin. Pharmacokinet.</u> , 2001, 40(7): 539-551
	57.	He et al., "A simplified system for generating recombinant adenoviruses," <u>Proc. Natl. Acad. Sci. USA</u> , 1998, 95:2509-2514
	58.	Hodges and Chan, "Locations of Oligosaccharide Chains in Human α 1-Protease Inhibitor and Oligosaccharide Structures at Each Site," <u>Biochemistry</u> , 1982, 21:2805-2810
	59.	Hodges et al., "Structure of the Oligosaccharide Chains in Human α 1-Protease Inhibitor," <u>J. Biol. Chem.</u> , 1979, 254(17):8208-8212
	60.	Hovgaard et al., "Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF," <u>Eur. J. Clin. Inv.</u> , 1992, 22:45-49

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-019US1	Application No. 10/530,849
	Applicant Michele Orlando et al.		
	Filing Date January 19, 2006	Group Art Unit 1623	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	61.	Hovinen et al., "Ethyl[2-deoxy-5-0-(4,4'-dimethoxytrityl)- α - and β -D-erythro-pentofuranosyl] acetates as versatile intermediates in nucleic acid chemistry," <u>Nucleosides Nucleotides</u> , 1999, 18:1263-1264
	62.	Iakovenko et al., "Semi-synthetic Rab proteins as tools for studying intermolecular interactions," <u>FEBS Letters</u> , 2000, 468:155-158
	63.	Ingenito et al., "Solid Phase Synthesis of Peptide C-Terminal Thioesters by Fmoc/t-Bu Chemistry," <u>J. Am. Chem. Soc.</u> , 1999, 121:11369-11374
	64.	Jaques et al., "N.M.R. spectroscopy and calcium binding of sialic acids: N-glycolylneuraminic acid and periodate-oxidized N-acetylneuraminic acid," <u>Carb. Res.</u> , 1980, 83:21-32
	65.	Karpusas et al., "The crystal structure of human interferon β at 2.2-Å resolution," <u>Proc. Natl. Acad. Sci. USA</u> , 1997, 94:11813-11818
	66.	Kaufman et al., "Synthesis, Processing, and Secretion of Recombinant Human Factor VIII Expressed in Mammalian Cells," <u>J. Biol. Chem.</u> , 1988, 263(13):6352-6362
	67.	Kaushansky et al., "Role of Carbohydrate in the Function of Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Biochemistry</u> , 1987, 26:4861-4867
	68.	Keene et al., "Expression of Biologically Active Human Follitropin in Chinese Hamster Ovary Cells," <u>J. Biol. Chem.</u> , 1989, 264(9):4769-4775
	69.	Kochendoerfer et al., "Design and Chemical Synthesis of a Homogeneous Polymer-Modified Erythropoiesis Protein," <u>Science</u> , 2003, 299(5608):884-887
	70.	Kraehenbuhl et al., "Preparation and characterization of an immuno-electron microscope tracer consisting of a heme-octapeptide coupled to Fab," <u>J. Exp. Med.</u> , 1974, 139:208-223
	71.	Lahiri et al., "Antithrombin-Heparin Cofactor: An Inhibitor of Plasma Kallikrein," <u>Arch. Biochem. Biophys.</u> , 1976, 175:737-747
	72.	Lapthorn et al., "Crystal structure of human chorionic gonadotropin," <u>Nature</u> , 1994, 369:455-461
	73.	Levy et al., "Recombinant Antithrombin: Production and Role in Cardiovascular Disorder," <u>Sem. Thromb. Hem.</u> , 2001, 27(4):405-416
	74.	Li et al., "Direct preparation of peptide thioesters using an Fmoc solid-phase method," <u>Tetrahedron Lett.</u> , 1998, 39(47):8669-8672
	75.	Lin et al., "L-Cysteine as a water-soluble cation scavenger in the removal of the 2,4,6-trimethoxybenzyl group from thiols," <u>Tetrahedron Lett.</u> , 2002, 43:4531-4533
	76.	March, "Delocalized Chemical Bonding," <u>Adv. Org. Chem.</u> , 1992, 4th Edition, John Wiley and Sons, New York, Chapter 2 pp. 26-292
	77.	Masamune et al., "A General, Selective Synthesis of Thiol Esters," <u>Can. J. Chem.</u> , 1975, 53:3693-3695
	78.	Masamune et al., "Tylonolide Hemiacetal, the Aglycone of Tylosin, and Its Partial Synthesis," <u>J. Am. Chem. Soc.</u> , 1976, 98:7874-7875
	79.	Masuda et al., "Synthesis and Anti-Influenza Evaluation of Orally Active Bicyclic Ether Derivatives Related to Zanamivir," <u>Bioorganic & Medicinal Chemistry Letters</u> , 2003, 13:669-673
	80.	Mega et al., "Studies on the Oligosaccharide Chains of Human α_1 -Protease Inhibitor. I. Isolation of glycopeptides," <u>J. Biol. Chem.</u> , 1980, 255(9):4053-4056
	81.	Mega et al., "Studies on the Oligosaccharide Chains of Human α_1 -Protease Inhibitor. II. Structure of oligosaccharides," <u>J. Biol. Chem.</u> , 1980, 255(9):4057-4061

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-019US1	Application No. 10/530,849
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Michele Orlando et al.	
		Filing Date January 19, 2006	Group Art Unit 1623
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	82.	Menache, "Antithrombin III: Introduction," <u>Semin. Hematol.</u> , 1991, 28:1-2
	83.	Menache et al., "Antithrombin III: physiology, deficiency, and replacement therapy," <u>Transfusion</u> , 1992, 32:580-588
	84.	Ming et al., "Interleukin 6 is the Principal Cytolytic T Lymphocyte Differentiation Factor for Thymocytes in Human Leukocyte Conditioned Medium," <u>J. Mol. Cell. Immunol.</u> , 1989, 4:203-212
	85.	Moonen et al., "Increased biological activity of deglycosylated recombinant human granulocyte/macrophage colony-stimulating factor produced by yeast or animal cells," <u>Proc. Natl. Acad. Sci. USA</u> , 1987, 84:4428-4431
	86.	Mori et al., "The Activation of Type 1 and Type 2 Plasminogen by Type I and Type II Tissue Plasminogen Activator," <u>J. Biol. Chem.</u> , 1995, 270(7):3261-3267
	87.	Muir et al., "Expressed protein ligation: A general method for protein engineering," <u>Proc. Natl. Acad. Sci. USA</u> , 1998, 95:6705-6710
	88.	Mukaiyama et al., "Peptide Synthesis via Oxidation-Reduction Condensation by the Use of Non-metallic Compound as a Mercaptan Scavenger," <u>Bull. Chem. Soc. Jpn.</u> , 1970, 43:1271
	89.	Mumberg et al., "Regulatable promoters of <i>Saccharomyces cerevisiae</i> : comparison of transcriptional activity and their use for heterologous expression," <u>Nucl. Acids Res.</u> , 1994, 22(25):5767-5768
	90.	Murano et al., "Some properties of antithrombin-III and its concentration in human plasma," <u>Thromb. Res.</u> , 1980, 18:259-262
	91.	Ohta et al., "Usefulness of Glycopeptide Mapping by Liquid Chromatography/Mass Spectrometry in Comparability Assessment of Glycoprotein Products," <u>Biologicals</u> , 2002, 30(3):235-244
	92.	Okamoto et al., "Purification and Characterization of Three Forms of Differently Glycosylated Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Arch. Biochem. Biophys.</u> , 1991, 286(2):562-568
	93.	Olson et al., "Role of the Antithrombin-binding Pentasaccharide in Heparin Acceleration of Antithrombin-Proteinase Reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement," <u>J. Biol. Chem.</u> , 1992, 267(18):12528-12538
	94.	Olson and Björk, "Predominant Contribution of Surface Approximation to the Mechanism of Heparin Acceleration of the Antithrombin-Thrombin Reaction. Elucidation from salt concentration effects," <u>J. Biol. Chem.</u> , 1991, 266(10):6353-6364
	95.	Opal et al., "Antithrombin, heparin, and heparan sulfate," <u>Crit. Care Med.</u> , 2002, 30(5):S325-S331
	96.	Pelter et al., "Synthesis of Thioesters by Reactions of Carboxylic Acids with Tris-(ethylthio)borane," <u>J. Am. Chem. Soc., Perkin Trans I</u> , 1977, 1672-674
	97.	Peterson, <u>The Physiological Inhibitions of Blood Coagulation and Fibrinolysis</u> , 1979, Elsevier/North-Holland Biomedical Press, p. 43
	98.	Pike et al., "Heparin-dependent Modification of the Reactive Center Arginine of Antithrombin and Consequent Increase in Heparin Binding Affinity," <u>J. Biol. Chem.</u> , 1997, 272 32:19652-19655
	99.	Ragnhammar et al., "Induction of Anti-Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (<i>Escherichia coli</i> -Derived) Antibodies and Clinical Effects in Nonimmunocompromised Patients," <u>Blood</u> , 1994, 84(12):4078-4087
	100.	Rapoport et al., "Protein transport across the eukaryotic endoplasmic reticulum and bacterial inner membranes," <u>Annu. Rev. Biochem.</u> , 1996, 65:271-303

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-019US1	Application No. 10/530,849
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Michele Orlando et al.	
		Filing Date January 19, 2006	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	101.	Reddy et al., "Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C," <u>Advanced Drug Delivery Reviews</u> , 2002, 54:571-586
	102.	Reischl (ed.), <u>Molecular Diagnosis of Infectious Diseases</u> , 1997, Vol. 13, Totowa NJ, Humana Press Inc. (TOC Only)
	103.	Reidhaar-Olson et al., "Identification of Residues Critical to the Activity of Human Granulocyte Colony-Stimulating Factor," <u>Biochemistry</u> , 1996, 35:9034-9041
	104.	Revoltella et al., "Natural and Therapy-Induced Anti-GM-CSF and Anti-G-CSF Antibodies in Human Serum," <u>Leukemia and Lymphoma</u> , 1997, 26:29-34
	105.	Roemisch et al., "Antithrombin: a new look at the actions of a serine protease inhibitor," <u>Blood Coagul. Fibrinolysis</u> , 2002, 13:657-670
	106.	Rosenberg, "Role of heparin and heparinlike molecules in thrombosis and atherosclerosis," <u>Fed. Proc.</u> , 1985, 44:404-409
	107.	Rosenberg et al., "Antithrombin-III," <u>Rev. Hematol.</u> , 1986, 2:351-416
	108.	Schlesinger, "Alphaviruses – vectors for the expression of heterologous genes," <u>Trends Biotech.</u> , 1993, 11:18-22
	109.	Schröter et al., "Male-specific Modification of Human CD52," <u>J. Biol. Chem.</u> , 1999, 274(42):29862-29873
	110.	Shin et al., "Fmoc-Based Synthesis of Peptide-Thioesters: Application to the Total Chemical Synthesis of a Glycoprotein by Native Chemical Ligation," <u>J. Am. Chem. Soc.</u> , 1999, 121:11684-11689
	111.	Spellman et al., "Carbohydrate Structures of Human Tissue Plasminogen Activator Expressed in Chinese Hamster Ovary Cells," <u>J. Biol. Chem.</u> , 1989, 264(24):14100-14111
	112.	Stetsenko and Gait, "Efficient Conjugation of Peptides to Oligonucleotides by "Native Ligation," <u>J. Org. Chem.</u> , 2000, 65:4900-4908
	113.	Stewart et al., "Identification of the Mechanism Responsible for the Increased Fibrin Specificity of TNK-Tissue Plasminogen Activator Relative to Tissue Plasminogen Activator," <u>J. Biol. Chem.</u> , 2000, 275(14):10112-10120
	114.	Tam et al., "Peptide Synthesis Using Unprotected Peptides Through Orthogonal Coupling Methods," <u>Proc. Natl. Acad. Sci. USA</u> , 1995, 92:12485-12489
	115.	Tebbutt, "Technology evaluation: transgenic α -1-antitrypsin (AAT), PPL Therapeutics," <u>Curr. Opin. Mol. Ther.</u> , 2000, 2(2):199-204
	116.	Thim et al., "Amino Acid Sequence and Posttranslational Modification of Human Factor VII _a from Plasma and Transfected Baby Hamster Kidney Cells," <u>Biochemistry</u> , 1988, 27:7785-7793
	117.	Toole et al., "Molecular cloning of a cDNA encoding human antihaemophilic factor," <u>Nature</u> , 1984, 312:342-347
	118.	Travis and Salvesen, "Human plasma proteinase inhibitors," <u>Ann. Rev. Biochem.</u> , 1983, 52:655-709
	119.	Veronese et al., "Peptide and Protein PEGylation – A Review of Problems and Solutions," <u>Biomaterials</u> , 2001, 22(5):405-417
	120.	Wadhwa et al., "Immunogenicity of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Products in Patients Undergoing Combination Therapy with GM-CSF," <u>Clin. Cancer Res.</u> , 1999, 5:1351-1361

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-019US1	Application No. 10/530,849
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Michele Orlando et al.	
		Filing Date January 19, 2006	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	121.	Watanabe et al., "A facile synthesis of carboxylic thiol esters from carboxylic acids and thiols," <u>Chem. Lett.</u> , 1976, 741-742
	122.	Weisshaar et al., "NMR investigations of the N-linked oligosaccharides at individual glycosylation sites of human lutropin," <u>Eur. J. Biochem.</u> , 1991, 195:257-268
	123.	Wright et al., "High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep," <u>Biotechnology</u> , 1991, 9:830-834
	124.	Yoshitake et al., "Nucleotide Sequence of the Gene for Human Factor IX (Antihemophilic factor B)," <u>Biochemistry</u> , 1985, 24:3736-3750

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	